This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order with a ceiling value of $2,973.05. The award was made by the Defense Logistics Agency (DLA) on December 4, 2024, with a period of performance through December 5, 2024. The contract is for the pharmaceutical product Quillivant XR 25 mg/5 ml suspension, 120 ml. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. This contract award is not associated with any set-aside designation.
Generated 3/5/25, 10:10 AM